98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jclinepi.2025.111935 | DOI Listing |
Crit Care Explor
September 2025
Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA.
Knee Surg Sports Traumatol Arthrosc
September 2025
University Clinic for Orthopedic Surgery and Traumatology, Kantonsspital Baselland, Bruderholz, Switzerland.
Kinematic alignment is increasingly adopted in total knee arthroplasty (TKA) as a patient-specific strategy to restore native joint anatomy. However, its reliance on static radiographic measurements may not adequately reflect real-world functional biomechanics. This editorial underscores the importance of complementing static assessment with kinetic principles.
View Article and Find Full Text PDFJ Med Educ Curric Dev
September 2025
Department of General Pediatrics, Pediatric Cardiology and Neonatology, Medical Faculty, University Children's Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Background: Medical education has been experiencing a transition from time- to competency-based. Since their introduction by Olle ten Cate in 2005, entrustable professional activities are a part of this process. We implemented a set of EPAs for the first 3 years of training at our hospital, encompassed by informational materials for trainees and supervisors.
View Article and Find Full Text PDFPerspect Biol Med
September 2025
The effects of climate change harms upon public health could be disastrous. Many have likened the urgency and peril associated with our global situation to living in a house on fire. This article uses the housefire metaphor to consider how public health teams and others can encourage actions that lessen climate-related harms.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
August 2025
Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI. Electronic address:
Blinatumomab is a bispecific T-cell engager that has recently transformed front-line treatment for many patients with Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). It was originally studied in relapsed/refractory disease, then moved to targeting measurable residual disease (MRD), and has since been shown to improve outcomes for almost every age group when added to consolidation chemotherapy. The evidence supporting blinatumomab is most robust in adult and standard-risk pediatric age groups, but its benefit in adolescents and young adults and high-risk pediatric patients is not yet understood.
View Article and Find Full Text PDF